Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Trial Profile

Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Crenolanib (Primary) ; Azacitidine; Cytarabine; Etoposide; Fludarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AROG Pharmaceuticals
  • Most Recent Events

    • 14 Oct 2015 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
    • 14 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 31 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top